Relief for Teva as longer-lasting Copaxone gets US nod
This article was originally published in Scrip
Executive Summary
The US FDA has approved Teva Pharmaceuticals' supplemental new drug application (sNDA) for three-times-a-week Copaxone (40mg injection). Teva has a lot riding on the new formulation of the multiple sclerosis drug, with the first patent expiries of the old Copaxone (20mg daily injection) coming in May this year. Teva had Copaxone revenues in excess of $4bn last year.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.